Teva & Norton v. Cipla: Inhaled Corticosteroid Patent Dispute Consolidated in NJ
Teva Pharmaceutical Industries and Norton (Waterford) Limited brought a patent infringement action against Cipla Limited in the District of New Jersey, asserting three patents covering beclomethasone dipropionate 40 mcg. Filed in May 2024 and closed in March 2025 after 319 days, the case was terminated via consolidation rather than a merits ruling.
Three-patent inhaler dispute ends in consolidation, not judgment
On 6 May 2024, Teva Pharmaceutical Industries, Ltd. and Norton (Waterford) Limited filed a patent infringement complaint against Cipla Limited in the U.S. District Court for the District of New Jersey. The action asserted three utility patents — US11793953B2, US11896759B2, and US11865247B2 — covering formulations and delivery of beclomethasone dipropionate at 40 mcg, an inhaled corticosteroid used in asthma and COPD management. The structure of the suit is consistent with a Hatch-Waxman ANDA challenge, in which a generic manufacturer’s abbreviated new drug application triggers a patent holder’s right to sue within the statutory 45-day window.
The case was closed on 21 March 2025, after 319 days, with the basis of termination recorded as ‘Case Consolidated.’ This procedural outcome means the action was merged into a related or lead case rather than resolved on the merits. Neither a final judgment of infringement or non-infringement, nor a settlement with publicly disclosed terms, appears in the docket. For Cipla, consolidation does not extinguish the underlying patent dispute; the claims continue in the consolidated proceeding. For Teva and Norton, the asserted patents remain at issue.
A 319-day timeline from filing to consolidation is consistent with early-stage procedural management in multi-case Hatch-Waxman litigation, where courts routinely merge parallel actions involving overlapping patents and products. The October 2024 ESI stipulation — adopting Delaware’s Default Standard — suggests the parties were preparing for substantive discovery before the court determined consolidation was appropriate. What remains unknown from the public record is whether the consolidated proceeding involves additional patent holders, additional ANDA filers, or a broader set of asserted patents beyond the three identified here.
Filing to Case Consolidated in 319 days
319-day lifespan before consolidation — shorter than typical NJ pharma ANDA cases
Case consolidated: what this means for Teva, Norton, and Cipla
Consolidation merges cases — no merits ruling yet
A ‘Case Consolidated’ termination means this docket number was merged into a lead or related proceeding under Federal Rule of Civil Procedure 42(a). The court found the cases share common questions of law or fact. Importantly, consolidation does not dismiss the claims — all three patents and the infringement allegations remain live in the consolidated action. No judgment was entered on validity, infringement, or enforceability at this stage.
Claims survive consolidationTeva and Norton retain all patent rights asserted
Consolidation is neutral for the plaintiffs in terms of substantive patent rights. Teva and Norton’s three beclomethasone dipropionate patents — US11793953B2, US11896759B2, and US11865247B2 — remain enforceable and in active dispute. The merged proceeding may offer Teva efficiencies if multiple generic ANDA filers are now addressed in one action, but it also increases procedural complexity and may extend the overall timeline to a final ruling.
Patents remain enforceableCipla faces continued exposure in the consolidated action
For Cipla, consolidation does not reduce its legal exposure. The infringement claims against its beclomethasone dipropionate 40 mcg ANDA product persist in the merged case. However, consolidation may provide Cipla with strategic benefit if co-defendants share invalidity or non-infringement arguments, enabling coordinated defense. The lack of a merits ruling at this stage means Cipla’s path to market for the generic product remains contingent on the consolidated proceeding’s outcome.
Dispute continues in merged caseGeneric inhaler market entry hinges on consolidated outcome
Beclomethasone dipropionate is a well-established inhaled corticosteroid in the asthma and COPD market. With three overlapping formulation patents asserted, the commercial stakes for generic entry are significant. Consolidation typically signals that the court has identified related ANDA challenges — suggesting a competitive generic landscape. Resolution of the consolidated case will define when, if ever, Cipla and any co-defendants may launch a competing beclomethasone 40 mcg product without patent risk.
Generic entry timeline uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Teva Pharmaceutical Industries, Ltd. | Company | Global branded pharma group — holder of US11793953B2, US11896759B2, and US11865247B2Search in Eureka ↗ |
| Co-Plaintiff | Norton (Waterford) Limited | Individual | Search in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Cipla Limited — multinational generic pharmaceutical manufacturer, India-headquarteredSearch in Eureka ↗ |
| Plaintiff counsel | Christine Clark | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Hector Daniel Ruiz | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Selena Miriam Ellis | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | DEMANT | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’reilly Falanga, LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Loly G. Tor | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant law firm | K&L Gates LLP | Law Firm | Representing Cipla LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text in this case is not a merits ruling but an ESI (electronically stored information) protocol stipulation entered in October 2024. It reflects the parties’ agreement to govern document discovery using Delaware’s Default Standard — a procedural step, not a finding on infringement or validity. The case was subsequently consolidated rather than adjudicated, meaning no judicial determination of the merits of Teva and Norton’s infringement claims against Cipla was issued under this docket number. The substantive dispute over the three beclomethasone dipropionate patents continues in the consolidated proceeding.
US11793953B2, US11896759B2 & US11865247B2 — Beclomethasone Dipropionate Inhaler Formulations
The three asserted patents — US11793953B2, US11896759B2, and US11865247B2 — cover formulations and methods relating to beclomethasone dipropionate (BDP) at 40 mcg for inhalation, a corticosteroid widely used in the treatment of asthma and chronic obstructive pulmonary disease. The application numbers (US17/957079, US17/949483, US17/847968) fall within a narrow filing window, suggesting a coordinated continuation or divisional prosecution strategy designed to maximise claim coverage across the product’s formulation space. This type of late-filing cluster is characteristic of branded pharmaceutical companies seeking to extend market exclusivity as an ANDA filing window approaches.
For competitors and generic manufacturers, the overlapping scope of these three patents — filed within weeks of each other and covering related aspects of the same product — represents a substantive freedom-to-operate challenge. Any ANDA applicant seeking to market a beclomethasone dipropionate 40 mcg inhaler product must independently assess each patent’s claims for validity and non-infringement. The close application dates and shared technical domain suggest shared prosecution history and potentially overlapping claim scope, raising both double-patenting and design-around complexity for generic entrants.
Should your team run an FTO against US11793953B2, US11896759B2 & US11865247B2?
Any pharmaceutical company developing, filing an ANDA for, or commercialising a beclomethasone dipropionate 40 mcg inhalation product should treat these three patents as high-priority FTO targets. The active Hatch-Waxman litigation in the District of New Jersey — now consolidated — confirms that Teva and Norton are actively enforcing this portfolio. R&D teams formulating inhaled corticosteroids, and regulatory affairs groups preparing ANDA Paragraph IV certifications, should ensure these patents are included in their clearance analysis before any NDA or ANDA submission.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claim-level coverage across all three asserted patents simultaneously, identify prosecution history estoppel, and surface related pending continuations that could extend risk. Rather than running three sequential manual searches, Eureka consolidates claim mapping, prior art identification, and portfolio gap analysis into a single workflow — allowing teams to assess and document FTO positions faster and with greater confidence ahead of ANDA filing or product launch decisions.
Run a freedom-to-operate analysis on US11793953B2 to assess your product’s exposure
Run FTO in Eureka →Related Hatch-Waxman inhaled corticosteroid patent cases in the District of New Jersey
Explore parallel ANDA infringement actions involving inhaled corticosteroid formulation patents litigated in the U.S. District Court for the District of New Jersey.
What this case signals for the inhaled corticosteroid IP landscape
Multi-patent Hatch-Waxman suits over inhaler formulations are consolidating in NJ — signalling competitive generic pressure on beclomethasone products.
Three-patent stacking raises the invalidity challenge bar for generics
Teva and Norton’s assertion of three closely related formulation patents — US11793953B2, US11896759B2, and US11865247B2 — creates overlapping claim coverage that any generic entrant must overcome in full. Invalidity of one patent does not automatically clear the path; each must be addressed independently, increasing the cost and complexity of Cipla’s defense.
Court-ordered ESI protocol signals substantive discovery was underway
The October 2024 ESI stipulation adopting Delaware’s Default Standard — before consolidation — indicates the parties had begun preparing for meaningful document discovery. This suggests the case had progressed beyond preliminary motions before the court determined consolidation was appropriate, consistent with a complex multi-party Hatch-Waxman proceeding rather than a quick procedural dismissal.
Teva v Cipla — key questions answered
Case No. 2:24-cv-05856 was closed on 21 March 2025 with a basis of termination of ‘Case Consolidated.’ No merits ruling on infringement or validity was issued under this docket number. The claims involving Teva and Norton’s three beclomethasone dipropionate patents continue in the consolidated proceeding.
Teva Pharmaceutical Industries and Norton (Waterford) Limited asserted three U.S. patents: US11793953B2 (App. No. US17/957079), US11896759B2 (App. No. US17/949483), and US11865247B2 (App. No. US17/847968). All three relate to beclomethasone dipropionate 40 mcg inhalation formulations.
A ‘Case Consolidated’ termination under Federal Rule of Civil Procedure 42(a) means the court merged this action with a related proceeding sharing common questions of law or fact. In Hatch-Waxman litigation, consolidation typically occurs when multiple generic ANDA filers face the same branded patents. The underlying claims are not dismissed — they continue in the lead or consolidated case.
This case asserts three active utility patents covering beclomethasone dipropionate 40 mcg inhaler formulations, and the case was consolidated rather than resolved on the merits. This suggests that as of March 2025, Teva and Norton are continuing to assert these patents in a consolidated proceeding. The patents should be treated as actively enforced until a final court ruling or PTAB decision establishes otherwise.
The parties’ October 2024 stipulation to apply Delaware’s Default ESI Standard — rather than New Jersey’s own defaults — is a common practice in Hatch-Waxman cases in the District of New Jersey and reflects the sophistication of pharmaceutical patent litigation. It indicates that substantive document discovery was being prepared before the court ordered consolidation, suggesting the case had advanced beyond initial pleadings before being merged.
PatSnap Eureka searches patents and litigation data to answer instantly.